Fact CheckerSign in

NCT00368095Active, not recruiting

Rajavithi Health Promotion Project (Population Base Cohort)

The Rajavithi Prospective Cohort Study on Community's Member Health (HPH-cohort Study)

Source: ClinicalTrials.gov · Last updated 6 May 2022

Brief summary (registry, in English)

Metabolic Syndrome (hypertension, diabetes mellitus, obesity, cerebrovascular-cardiovascular disease) In Community Survey was performed in central Bangkok. Prospective Cohort and intensive educated intervention (health promotion program in specific high risk groups) were performed. The aim of the study is to identify high risk patients who can develop serious complications from metabolic syndrome. An analysis of health outcomes in multiple dimensions will be performed.

Status (registry)
Active, not recruiting
Study type
Observational
Enrollment
2000 (estimated)
First submitted
23 Aug 2006
Start date
Aug 2006
Primary completion date
Dec 2026
Lead sponsor
Department of Medical Services Ministry of Public Health of Thailand
NCT number
NCT00368095

What you commit to

  • Study type: Observational
  • Planned participants: 2000
  • From Aug 2006 to the primary completion date, Dec 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

  • Age 16 years or more
  • Informed consent
  • Living in selected community (Health Promotion area of Rajavithi Hospital)

Age in the registry: 16 years to 120 years · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Rajavithi Hospital
Coordinator of this site? Confirm its status
BangkokThailandUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.